CAPRICOR THERAPEUTICS

Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

13 5 2025 16:05:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer

13 5 2025 09:00:01 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13

06 5 2025 09:15:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

05 5 2025 08:00:01 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day

01 4 2025 09:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

19 3 2025 16:05:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

17 3 2025 09:25:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19

11 3 2025 09:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025

07 3 2025 09:25:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy

04 3 2025 07:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Participate in Upcoming Investor Conferences

10 2 2025 09:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

02 1 2025 09:15:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present at Upcoming Investor Conferences

02 12 2024 16:15:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency

20 11 2024 09:00:01 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

13 11 2024 16:01:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting

12 11 2024 09:00:01 提供 Nasdaq GlobeNewswire

Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13

05 11 2024 09:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

18 10 2024 16:01:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock

17 10 2024 06:00:00 提供 Nasdaq GlobeNewswire

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

16 10 2024 16:17:48 提供 Nasdaq GlobeNewswire